$2.63
+1.15%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.80
From 52W high−43.07%
Volume1.09M
Market cap$113.87M
P/E (TTM)—
P/S (TTM)33.5x
Div yield—
Key dataOct 19, 2026
Open
$2.80
From 52W high
−43.07%
Volume
1.09M
Market cap
$113.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.0x
P/E (TTM)
—
RSI (14)
36.0
MomentumView details →
1D Return
+1.15%
YTD Return
−0.92%
SummaryUpdated Jun 1, 2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Wilmington, Delaware. The company went public in December 2017 and focuses on developing novel therapeutics for central nervous system disorders, particularly targeting the treatment of suicidal depression and bipolar depression. NRx has evolved from a pure research and development organization into a company pursuing a dual strategy of drug development and clinical service delivery through its subsidiary Hope Therapeutics.
Similar companies
Latest newsMore news →
NRx Pharmaceuticals announced completion of three commercial-condition process-validation lots of preservative-free ketamine ahead of the November 10 GDUFA goal date.9h agoThe FDA issued NRX Pharmaceuticals, Inc. a labeling review letter for preservative-free ketamine, classifying all requested changes as minor and requesting labels using the proprietary name under FDA review.4d agoNRx Defense Systems, an NRx company, was awarded an $11 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101 for treatment-resistant depression.19d ago